Search results
Results from the WOW.Com Content Network
Lutetium (177 Lu) oxodotreotide or 177 Lu dotatate, brand name Lutathera, is a chelated complex of a radioisotope of the element lutetium with dotatate, used in peptide receptor radionuclide therapy. Specifically, it is used in the treatment of cancers which express somatostatin receptors. [5] It is a radiolabeled somatostatin analog. [3] [6] [7]
DOTA-TATE can be reacted with the radionuclides gallium-68 (T 1/2 = 68 min), lutetium-177 (T 1/2 = 6.65 d) and copper-64 (T 1/2 = 12.7 h) to form radiopharmaceuticals for positron emission tomography (PET) imaging or radionuclide therapy. 177 Lu DOTA-TATE therapy is a form of peptide receptor radionuclide therapy (PRRT) which targets ...
Lutetium (177 Lu) vipivotide tetraxetan, sold under the brand name Pluvicto, is a radiopharmaceutical medication used for the treatment of prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC). [5] [6] Lutetium (177 Lu) vipivotide tetraxetan is a targeted radioligand therapy. [6] [8]
Radiation from lutetium (177 Lu) oxodotreotide can cause damage when the medicine passes through tubules in the kidney. [45] Arginine/lysine can be used to reduce renal radiation exposure during peptide receptor radionuclide therapy with lutetium ( 177 Lu) oxodotreotide.
Lutetium-177 labelled edotreotide (177 Lu-DOTA-TOC), with the trade name Solucin, is the subject of a phase 3 clinical trial for treatment of GEP-NETs. [ 7 ] [ 8 ] It was granted orphan drug designation by the European Medicines Agency in 2014.
Lutetium (177 Lu) chloride is a radioactive compound used for the radiolabeling of pharmaceutical molecules, aimed either as an anti-cancer therapy or for scintigraphy (medical imaging). [ 5 ] [ 6 ] It is an isotopomer of lutetium(III) chloride containing the radioisotope 177 Lu , which beta decays with a half-life of 6.64 days.
Lutetium salts are then selectively washed out by suitable complexing agent. Lutetium metal is then obtained by reduction of anhydrous LuCl 3 or LuF 3 by either an alkali metal or alkaline earth metal. [22] 2 LuCl 3 + 3 Ca → 2 Lu + 3 CaCl 2. 177 Lu is produced by neutron activation of 176 Lu or by indirectly by neutron activation of 176 Yb ...
This compound is called 177 Lu-HH1 or lutetium (177 Lu) lilotomab satetraxetan (trade name Betalutin). [1] As of 2016, a phase 1/2 clinical trial in people with non-Hodgkin lymphoma was underway. [4] The satetraxetan structure chelating lutetium-177 [5]